BOSTON and NEW YORK, December 20, 2019: Morgan Lewis represented Vyera Pharmaceuticals LLC in a commercialization and license agreement and a related supply agreement with CytoDyn Inc. that grants an exclusive license to Vyera to market and distribute leronlimab in the United States for the treatment of HIV. Vyera will pay upfront, regulatory and sales-based milestone payments totaling up to $87.5 million, as well as a royalty on net sales of 50%. Additionally, Vyera will purchase $4 million of CytoDyn common stock.
Vyera is a US-based biopharmaceutical company committed to developing and commercializing treatments that address serious and rare diseases with high unmet medical needs. CytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab. Leronlimab (PRO 140) is a viral-entry inhibitor for the treatment of deadly diseases such as HIV and cancer.
Partners Jay Carrigan and Steve Navarro led the Morgan Lewis team advising Vyera along with partner Chris Halliday, associate Natalie Nicelli, and of counsel Al Bristow.